Rally in opposition to Bill No. 103 "whose primary purpose is to regulate supervised consumption sites in order to promote harmonious coexistence with the community" Français
TIOHTIA:KE, QC, MONTRÉAL, June 2, 2025 /CNW/ - On the eve of the parliamentary debates on Bill 103, the Association Québécoise pour la Promotion de la Santé des Personnes Utilisateurs de Drogues (AQPSUD) and the Association pour la Défense des Droits et l'Inclusion des personnes qui Consommation des drogues du Québec (ADDICQ) are joining forces to denounce a direct attack on the rights and health of people who use drugs. To make their demands heard, a rally will be held this Tuesday, June 3, at 2 p.m., at the Fontaine de Tourny in front of the National Assembly.
While they talk, we die
On May 6, 2025, Lionel Carmant, Health and Social Services Minister, introduced Bill 103. Since then, many groups have expressed their opposition to a bill that unnecessarily increases the administrative burden on organizations working in harm reduction and homelessness. Again, elected officials have chosen to talk about us, without us. Even though supervised consumption services have proven to be effective in the fight against the overdose crisis, the minister is proposing a legislative framework without any consultation, thereby jeopardizing human lives and the fragile social safety net that supports them.
Bill 103 also shifts responsibility for "social co-existence" to organizations, while reinforcing the stigma of people who use drugs and those who are homeless. It reflects a chronic mistrust of community expertise and challenges its autonomy. It is time for the voices of those most affected to be heard, because it is they—we—who die when the government complicates access to services.
Time is running out to destigmatize
History has shown that prohibition drives people to use in isolation, which increases the risks. Too often, supervised consumption sites are the only safe spaces available. By compromising their operations, Bill 103 threatens to force many of them out of business, putting lives at risk. We are calling for the complete abandonment of this bill and a clear shift toward the decriminalization of drugs.
There is an urgent need to invest heavily in affordable housing accessible to everyone and in harm reduction services, and to ensure the full inclusion of people who use drugs in the development of policies that affect them.
"The perception persists that repressive approaches will overcome drug consumption or drug use. It is time to change the paradigm and come up with more appropriate solutions. "
-Mario Gagnon, Chief Executive Officer of Point de Repères, at a citizens' meeting organized by L'Engrenage Saint-Roch: https://monsaintroch.com/2023/demystifier-le-monde-des-drogues/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
VIENNA, June 4, 2025 /CNW/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy (IgAN). Findings presented today at the 62 nd ERA Congress demonstrate sustained proteinuria remission, stable kidney function, and a reassuring safety profile. IgAN is the most common form of glomerular disease worldwide and a frequent cause of chronic kidney disease. Its pathogenesis is marked by inflammation and progressive kidney damage, which can lead to kidney failure. Many patients are unaware they have the condition until significant kidney damage has occurred, and 50% of IgAN patients will ultimately develop kidney failure. By targeting the APRIL pathway and reducing production of pathogenic galactose-debecause ofgA1), zigakibart addresses a key driver of disease progression. "Zigakibart is designed to intercept the initiating factor in IgAN pathogenesis, offering a new approach that may halt or significantly delay progression", explained lead investigator Professor Jonathan Barratt. The ADU-CL-19 trial included 40 adults with biopsy-confirmed IgAN and persistent proteinuria despite stable supportive therapy. Patients received zigakibart every two weeks via intravenous infusion or subcutaneous injection, in addition to maximally tolerated renin–angiotensin system inhibitors (RASi) unless RASi-intolerant – demonstrating efficacy beyond standard care. At Week 100, proteinuria was reduced by 60% from baseline. Over half of patients (55%) reached <500 mg/24 h, and 31% achieved <300 mg/24 h, indicating deeper remission. Estimated glomerular filtration rate (eGFR) remained stable across subgroups. "The consistency of eGFR stabilisation over 100 weeks, even across proteinuria response groups, is particularly encouraging," said Prof. Barratt. Treatment also led to sustained reductions in serum immunoglobulins, including a 74% drop in IgA and pathogenic Gd-IgA1, consistent with APRIL pathway inhibition. Zigakibart was well tolerated throughout. Most adverse events were mild or moderate, with no treatment-related serious infections or discontinuations. Infections were the most common AEs; the study coincided with a high prevalence of COVID-19. This is the longest duration of eGFR stabilisation reported for an anti-APRIL agent in IgAN. "These long-term results build confidence in zigakibart as a potential cornerstone therapy for IgAN," said Prof. Barratt. "We're excited to see how the upcoming Phase 3 trials will further define its role." The global Phase 3 BEYOND study is now evaluating zigakibart in a broader population, with primary proteinuria endpoints at 40 weeks and long-term kidney function through 104 weeks.
Montreal Gazette
3 hours ago
- Montreal Gazette
Safe consumption sites a ‘matter of life and death' in Montreal, consultations hear
Quebec Politics By The director of a much-discussed safe consumption site in Montreal delivered a heartfelt plea to the Quebec government on Wednesday, warning about the potential consequences of its proposed legislation on the sites. During consultations on the matter, Maison Benoît Labre's Andréane Désilets stressed how preserving access to the sites is 'literally a matter of life and death.' 'Throughout everything that will be said during these consultations, there is one undeniable reality,' Désilets told elected officials. 'Women, men — and often young people in extremely vulnerable situations — are dying from drug overdoses almost every day across Quebec.' Désilets was among those participating in consultations in Quebec City concerning Bill 103, the government's attempt to regulate how and where safe consumption sites can operate in the province. Tabled by Social Services Minister Lionel Carmant last month, the bill seeks to bar the sites from operating within 150 metres of a school or daycare. It would also give the government the authority to extend certain restrictions to organizations serving unhoused people. In an interview before Wednesday's hearing, Désilets said she feels the legislation is being rushed through and that it fails to take into account the impact it will have in cities such as Montreal. Though most safe consumption sites offer a variety of harm reduction services, they are intended to prevent overdoses by allowing people to consume their drugs under the observation of trained staff. There are five such sites operating in Montreal, not counting organizations that offer mobile services. According to the city, over the last five years, they have served more than 28,000 people. Given Montreal's density and its high number of daycares and schools, Désilets argued respecting the 150-metre radius is all but impossible in the city. The Maison Benoît Labre, which also offers transitional housing and drop-in services, is currently located 143 meters from an elementary school. Under the new legislation, it would need to relocate its safe consumption services within four years of the bill passing — a move the organization has estimated to cost at least $6 million. 'The costs are just tremendous, all for seven metres,' Désilets said, noting she has already begun looking for nearby alternatives. Désilets is calling on the province to offer financial compensation to any sites that would be forced to move. She also wants the government to help them through the relocation process to ensure services aren't interrupted. Responding to Désilets during the consultations, Carmant said the seven-metre difference in Maison Benoît Labre's case isn't the main issue. Rather, it's how close the site is to the school in general that raises concerns. 'It's really the proximity that is an issue,' Carmant said, adding that he's visited the centre several times. Maison Benoît Labre opened in a new location in St-Henri last spring. It initially faced strong opposition from neighbours, who say its opening led to an increase in drug consumption and crime in the neighbourhood. Désilets said many of those tensions have been resolved over the last year through concerted efforts, but she fears needing to move could undo all that progress. 'We would need to restart that entire process,' she said. At the end of her testimony on Wednesday, Désilets was asked what would happen if services in the Sud-Ouest neighbourhood were to be reduced. She pointed out how there's already a lack of similar services in the western part of the city, despite the needs being identified for years. Then she explained what Maison Benoît Labre sees on a day-to-day basis. 'We resuscitate people every day,' Désilets said. Many of them, she noted, are young adults who find themselves on their own after emerging from youth protection without adequate support. 'It doesn't make sense,' she added. 'It find it awful, and it's what's coming.'
Cision Canada
4 hours ago
- Cision Canada
SGS Acquires H2Safety to Optimize Emergency Management and Operational Safety for North American Industrial Sectors
CALGARY, AB, June 4, 2025 /CNW/ - SGS, the world's leading testing, inspection and certification company announces the acquisition of H 2 Safety Services Inc. (H 2 Safety), a North American market leader in emergency response management, Health Safety and Environment (HSE), training and emergency software services. Founded in 2004, H 2 Safety serves a wide range of industrial sectors including oil and gas, mining, transportation, utilities, renewables and government. With a unique focus on public consultation and regulatory compliance, H 2 Safety also excels in Indigenous relations and government relations. "Our approach to safeguarding critical infrastructure, communities, employees and natural environments is rooted in building authentic relationships and addressing community concerns transparently," said James Harasen, CEO and Chairman of H 2 Safety. "We are excited about joining SGS to expand our emergency management footprint while also leveraging SGS's proven expertise in delivering comprehensive HSE solutions across various industries." H 2 Safety's H2CommandCentre® platform is a robust emergency management application that empowers organizations with rapid and holistic incident management response capabilities. It activates emergency response teams including GIS and ICS experts, delivers rapid notifications, offers real-time check-ins, uses real-time maps to identify hazard zones while also generating lists of critical residents and stakeholders. With over 15,000 users, the platform is supporting organizations with achieving their operational safety objectives and business continuity, while also protecting people and the environment. "Operational integrity is at the core of SGS's corporate culture, since our customers entrust us with their quality assurance and operational fluidity needs in a wide range of industrial environments. Whether it's delivering inspections to monitor the integrity of oil pipelines or deterring wildlife from landing in hazardous substances, HSE is at the core of what we do. We also have a strong HSE record within our own operations, so we really walk the talk when it comes to protecting assets, employees and the environment," said Patrick Beck, Head of Industrial Services at SGS in North America. H 2 Safety contributes to achieving SGS's Strategy 27, which includes responding to megatrends driving growth in the TIC industry. One of these megatrends is innovation in digital capabilities and new technologies. Organizations in the industrial sector are investing more in digital transformation solutions to remain competitive and to increase market share. An end-to-end emergency management platform serves as a powerful digital tool to strengthen digital transformation when it comes to operational safety and compliance. Another megatrend driving growth in the TIC industry is ESG regulation and societal expectations. Optimizing HSE and emergency management, with a focus on Indigenous and community relations, positively contributes to achieving corporate environmental and social development objectives. With this acquisition, SGS is also building towards achieving the company's objective of doubling North American sales between 2023 to 2027. For media inquiries, please contact: ABOUT SGS SGS is the world's leading Testing, Inspection and Certification company. We operate a network of over 2,500 laboratories and business facilities across 115 countries, supported by a team of 99,500 dedicated professionals. With over 145 years of service excellence, we combine the precision and accuracy that define Swiss companies to help organizations achieve the highest standards of quality, compliance and sustainability. Our brand promise – when you need to be sure – underscores our commitment to trust, integrity and reliability, enabling businesses to thrive with confidence. We proudly deliver our expert services through the SGS name and trusted specialized brands, including Brightsight, Bluesign, Maine Pointe and Nutrasource. SGS is publicly traded on the SIX Swiss Exchange under the ticker symbol SGSN (ISIN CH1256740924, Reuters SGSN.S, Bloomberg SGSN:SW).
